Blastoma

Glioblastoma, the most common and deadly form of brain cancer, grows rapidly to invade and destroy healthy brain tissue. The tumor sends out cancerous tendrils into the brain that make surgical tumor removal extremely difficult or impossible. Now, Salk scientists have found the immunotherapy treatment anti-CTLA-4 leads to considerably greater…

Author of the article: Published Aug 02, 2023  •  2 minute read Marc Gilpin, Roy Scheider, and Lorraine Gary in Jaws 2 Photo by Getty /Bang Showbiz ‘Jaws 2’ actor Marc Gilpin has died at the age of 56. Advertisement 2 This advertisement has not loaded yet, but your article…

Marc Gilpin, who played the younger son of Roy Scheider’s Police Chief Martin Brody in Jaws 2, has died. He was 56. Gilpin died Saturday in Dallas after a long battle with glioblastoma, his older sister, Frasier actress Peri Gilpin, announced. After answering a casting call, Gilpin beat out hundreds…

Proceedings of the National Academy of Sciences, Volume 120, Issue 32, August 2023.

Glioblastoma (histology slide). Credit: Wikipedia/CC BY-SA 3.0 More than 14,490 people in the U.S. will be diagnosed with glioblastoma in 2023, according to the National Brain Tumor Society, and 10,000 people in the U.S. will die of the disease. The five-year survival rate is 6.9%, and the median length of…

A YOUNG mum who is battling terminal brain cancer says the upcoming EastEnders episode featuring Lola Pearce-Brown’s funeral will be ‘too hard’ to watch. Laura Mahon, 31, from St Helens, Merseyside, knows one day her family will have to go through the same heartache. 7 Laura Mahon was pregnant when…

John Wishman was diagnosed with the deadliest form of brain cancer, glioblastoma, in fall 2020. Two and a half years later, he’s still traveling and enjoying life — a rarity for a cancer with an average survival time of just 12 to 18 months.  Wishman, 61, of Buffalo, New York,…

A new “miracle” gel shows great promise for brain tumour treatment during lab tests at Johns Hopkins University. The gel is used to treat one of the most aggressive forms of brain tumour, glioblastoma, leaving patients with a diagnosed life expectancy of 12 – 18 months. The new treatment is…

The combination of oncolytic DNX-2401 virotherapy with pembrolizumab (Keytruda) failed to meet a phase I/II study's primary endpoint of objective response rate (ORR) in patients with recurrent glioblastoma, but did demonstrate a "notable survival benefit" in select patients. Among 49 patients who received DNX-2401 followed by pembrolizumab, the ORR was…

TORONTO – A new international study published in Nature Medicine and presented as a late-breaking abstract at the American Association of Neurological Surgeons (AANS) annual conference, shows great promise for patients with glioblastoma. Drs. Farshad Nassiri and Gelareh Zadeh, neurosurgeons at the University Health Network (UHN) in Toronto, published the…